DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CRISABOROLE

« Back to Dashboard

Clinical Trials for Crisaborole

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT03233529	Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis	Not yet recruiting	Pfizer	Phase 2	This study is being conducted to characterize the mechanism of action of crisaborole ointment 2%, by evaluation of efficacy and changes in key skin biomarkers in atopic dermatitis (AD) lesions treated with crisaborole ointment 2% over vehicle, in subjects with mild to moderate AD. Two identified AD skin lesions for each subject will be treated for the first 15 days, one with crisaborole ointment 2% and one with vehicle, in a blinded manner, and biopsies for biomarker analysis will be performed on the lesions. Following completion of the blinded treatment period, subjects will start the 28 day open label period during which all AD affected skin lesions will be treated with crisaborole ointment 2% twice daily.
NCT03260595	A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatit	Not yet recruiting	Pfizer	Phase 1	This is a Phase 1 parallel-cohort study of crisaborole ointment 2% to evaluate the skin irritation potential in adult Japanese healthy subjects in Cohort 1, and to evaluate the safety, tolerability and PK in adult Japanese subjects with mild to moderate AD in Cohort 2.
NCT03351114	Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea	Not yet recruiting	Pfizer	Phase 2	This is a pilot study to determine the safety and clinical efficacy of crisaborole 2% ointment in the treatment of morphea.
NCT03351114	Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea	Not yet recruiting	Duke University	Phase 2	This is a pilot study to determine the safety and clinical efficacy of crisaborole 2% ointment in the treatment of morphea.
NCT03356977	A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis	Not yet recruiting	Pfizer	Phase 4	This 4-week study will evaluate the safety, pharmacokinetics (PK), and efficacy of crisaborole ointment 2%, applied twice daily (BID) in subjects who are 3 months to less than 24 months of age with mild-to-moderate AD.

Clinical Trial Conditions for Crisaborole

Condition Name

Condition Name for Crisaborole
Intervention	Trials
Atopic Dermatitis	3
Healthy	2
Seborrheic Dermatitis	1
Morphea	1

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Crisaborole
Intervention	Trials
Dermatitis	5
Eczema	4
Dermatitis, Atopic	4
Dermatitis, Seborrheic	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Crisaborole

Trials by Country

Trials by Country for Crisaborole
Location	Trials
United States	10
Canada	1

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Crisaborole
Location	Trials
Kentucky	2
Arkansas	2
Connecticut	1
Virginia	1
Texas	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Crisaborole

Clinical Trial Phase

Clinical Trial Phase for Crisaborole
Clinical Trial Phase	Trials
Phase 4	3
Phase 2	2
Phase 1	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Crisaborole
Clinical Trial Phase	Trials
Not yet recruiting	5
Recruiting	2

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Crisaborole

Sponsor Name

Sponsor Name for Crisaborole
Sponsor	Trials
Pfizer	6
University of Alabama at Birmingham	1
Duke University	1

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Crisaborole
Sponsor	Trials
Industry	6
Other	2

Export unavailable in trial.
Subscribe for complete access.